Skip to content
Search

Latest Stories

Zentiva recalls Co-codamol effervescent tablets

Zentiva Pharma has recalled the batch of Co-codamol 30/500 effervescent tablets as a precautionary measure due to an “issue with the homogeneity of the batch”.

The company said some of the medicines were found to have “too little active ingredients (codeine phosphate and paracetamol) in them”, while “some may contain too much active ingredients”.


As per the current investigation, the tablets were identified where the content of both codeine and paracetamol was less than the label claimed.

The medicine with batch number 1K10121 was distributed first in the month of March this year.

Batch NumberExpiry DatePack SizeFirst Distributed
1K10121December 2023100March 2021

With this potential risk to the patients, the regulators advised that healthcare professionals immediately stop supplying the said batch of the medicine and "quarantine all remaining stock" and "return the said batch of tablets to their supplier". The regulators also suggested to contact all patients who have been dispensed the impacted batch and have asked them to “urgently return the stock to the pharmacy for replacement.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less